NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

No problems

"One problem. NWBO's OS is confounded questioning the validity of the data. NWBO said so, and regulators could easily reject the results as invalid."

should be stated, "no problems, NWBO's OS data is successful, there are confounding factors that still rebuke the truth that DCVax-L works.

When the OS data results are real and well received by doctors, scientist, and professionals but disagreed by confounding false statements there is no association regarding the truth and fiction since they are both independent from each other. Therefore, NWBO's DCVax-L prevails and should continue to move forward.